These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23761048)

  • 21. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
    Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
    Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of oral bioavailability enhancing formulations during drug discovery.
    Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
    Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs.
    Willmann S; Thelen K; Becker C; Dressman JB; Lippert J
    Eur J Pharm Biopharm; 2010 Sep; 76(1):83-94. PubMed ID: 20554023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction.
    Liu F; Zhuang X; Yang C; Li Z; Xiong S; Zhang Z; Li J; Lu C; Zhang Z
    Biopharm Drug Dispos; 2014 Jul; 35(5):296-307. PubMed ID: 24647883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.
    Ni Z; Talattof A; Fan J; Tsakalozou E; Sharan S; Sun D; Wen H; Zhao L; Zhang X
    AAPS J; 2017 Jul; 19(4):1045-1053. PubMed ID: 28357656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery.
    Thomas S; Brightman F; Gill H; Lee S; Pufong B
    J Pharm Sci; 2008 Oct; 97(10):4557-74. PubMed ID: 18300298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the Impact of Physiological Properties of the Gastrointestinal Tract On Drug In Vivo Performance Using Physiologically Based Biopharmaceutics Modeling and Virtual Clinical Trials.
    Jereb R; Opara J; Bajc A; Petek B
    J Pharm Sci; 2021 Aug; 110(8):3069-3081. PubMed ID: 33878322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling and Monte Carlo simulations in oral drug absorption.
    Dokoumetzidis A; Kosmidis K; Argyrakis P; Macheras P
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):200-5. PubMed ID: 15733215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting pharmacokinetics of drugs using physiologically based modeling--application to food effects.
    Parrott N; Lukacova V; Fraczkiewicz G; Bolger MB
    AAPS J; 2009 Mar; 11(1):45-53. PubMed ID: 19184451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A physiologic model for simulating gastrointestinal flow and drug absorption in rats.
    Willmann S; Schmitt W; Keldenich J; Dressman JB
    Pharm Res; 2003 Nov; 20(11):1766-71. PubMed ID: 14661920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology.
    Wu C; Sun L; Sun J; Yang Y; Ren C; Ai X; Lian H; He Z
    Int J Pharm; 2013 Sep; 453(2):300-6. PubMed ID: 23806811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts.
    Macheras P; Chryssafidis P
    Pharm Res; 2020 Sep; 37(10):187. PubMed ID: 32888087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
    Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
    Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.